國家衛生研究院 NHRI:Item 3990099045/4636
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 869403      在线人数 : 696
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/4636


    题名: An open, multi-center, phase II clinical trial to evaluate efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer preliminary report
    作者: Chao, Y;Li, CP;Chao, TY;Su, WC;Hsieh, RK;Wu, MF;Yeh, KH;Chen, LT;Cheng, AL
    贡献者: National Institute of Cancer Research
    摘要: Background: To evaluate the response rate and safety of weekly paclitaxel (Taxol) combination chemotherapy with UFT (tegafur, an oral 5-fluorouracil prodrug, and uracil at a 1:4 molar ratio) and leucovorin in patients with advanced gastric cancer. Methods: Patients with histologically confirmed, locally advanced or recurrent/metastatic gastric cancer were studied. Paclitaxel 1-hour infusion at a dose of 100 mg/m2 on days 1 and 8, and oral UFT 300 mg/m2/d plus leucovorin 90 mg/d were given starting from day 1 for 14 days, followed by a 7-day period without treatment, treatment repeated every 21 days. Results: From February 2003 to August 2004, 36 patients were enrolled. The median age was 60.8 years (range: 32 to 82). Among the 33 patients evaluable for tumor response, 1 achieved complete response and 12 partial response, with an overall response rate of 39.4% (95% CI: 11.2% to 53.0%). All 36 patients were evaluated for survival and toxicities. Median time to progression and overall survival were 4.1 months and 7.7 months, respectively. Major grade 3-4 toxicities were neutropenia in 15 patients (41.7%) and diarrhea in 7 patients (19.4%). Treatment was discontinued due to treatment-related toxicities in 2 patients (5.6%). No patient died of treatment-related toxicities. Conclusions: We conclude that this paclitaxel-containing regimen is effective and well tolerated in the treatment of advanced gastric cancer.
    日期: 2005-06
    關聯: Journal of Clinical Oncology. 2005 Jun;23(16):Abstract number 346S.
    Link to: http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/4156
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000230326602206
    显示于类别:[陳立宗] 會議論文/會議摘要

    文件中的档案:

    没有与此文件相关的档案.



    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈